Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2-HYPE: SGLT2 Inhibition in Hypertension
NCT06804161Phase 3Recruiting
- Start
- Dec 2025
- Primary completion
- May 2032
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) (2 arms). Primary endpoint: Time until first occurrence of cardiovascular event at 7 years. Started Dec 2025; status: recruiting.
02
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06804161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804161.